$8.07
0.283.59%
Ult. Agg.: Oct 19, 5:55 PM
$8.08
0.293.72%
BioCryst Pharma (BCRX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
BioCryst Pharma (BCRX) ha pubblicato l'ultima guidance il agosto 5, 2026 per fiscal year 2026. La società ha previsto un fatturato pari a $635M - $660M per il periodo.
Rispetto alle previsioni precedenti, BioCryst Pharma ha modificato le sue previsioni di fatturato da un intervallo precedente di .
BioCryst Pharma ha pubblicato {{revenueDirection}} aggiornamenti delle previsioni tra il {{revenuePriorRange}} e il BioCryst Pharma. 11
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.22 | $0.10 | $0.07 | $0.08 |
| Actual | $0.30 | $0.14 | $0.06 | $0.16 |
| Surprise | +36.4% | +40.0% | -21.4% | +100.0% |
| Revenue | ||||
| Estimate | $187.8M | $152.2M | $150.5M | $162.2M |
| Actual | $218.3M | $156.4M | $163.3M | $159.4M |
| Surprise | +16.2% | +2.79% | +8.46% | -1.76% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.11 | $0.12 | $0.08 | $0.13 |
| Revenue | ||||
| Consensus | $165.8M | $169.7M | — | — |
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $0.30 | $0.22 | 36.4 % |
| Q1 | May 6, 2026 | $0.14 | $0.10 | 40.0 % |
| Q4 | Feb 26, 2026 | $0.06 | $0.07 | -21.4 % |
| Q3 | Nov 3, 2025 | $0.16 | $0.08 | 100.0 % |
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $218.25M | $187.77M | 16.2 % |
| Q1 | May 6, 2026 | $156.41M | $152.16M | 2.79 % |
| Q4 | Feb 26, 2026 | $163.28M | $150.54M | 8.46 % |
| Q3 | Nov 3, 2025 | $159.40M | $162.24M | -1.76 % |